Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35,795 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
American Radium Society Appropriate Use Criteria for the use of liver-directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines.
Hallemeier CL, Sharma N, Anker C, Selfridge JE, Lee P, Jabbour S, Williams V, Liu D, Kennedy T, Jethwa KR, Kim E, Kumar R, Small W Jr, Tchelebi L, Russo S. Hallemeier CL, et al. Among authors: liu d. Cancer. 2023 Oct 15;129(20):3193-3212. doi: 10.1002/cncr.34931. Epub 2023 Jul 6. Cancer. 2023. PMID: 37409678
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada.
Wong JK, Lim HJ, Tam VC, Burak KW, Dawson LA, Chaudhury P, Abraham RJ, Meyers BM, Sapisochin G, Valenti D, Samimi S, Ramjeesingh R, Mujoomdar A, Martins I, Dixon E, Segedi M, Liu DM. Wong JK, et al. Among authors: liu dm. Cancer Treat Rev. 2023 Apr;115:102526. doi: 10.1016/j.ctrv.2023.102526. Epub 2023 Mar 2. Cancer Treat Rev. 2023. PMID: 36924644 Review.
When Ice Hurts.
Cardarelli-Leite L, Liu DM. Cardarelli-Leite L, et al. Int J Radiat Oncol Biol Phys. 2023 Dec 1;117(5):1048-1049. doi: 10.1016/j.ijrobp.2023.08.040. Int J Radiat Oncol Biol Phys. 2023. PMID: 37980135 No abstract available.
Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study.
Wang T, Zhang P, Di L, Wang X, Yang J, Tong Z, Liu J, Feng J, Liu D, Yu Q, Liu Y, Yu H, Jiang Z. Wang T, et al. Among authors: liu d. Transl Breast Cancer Res. 2022 Apr 30;3:15. doi: 10.21037/tbcr-21-42. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751509 Free PMC article.
35,795 results
You have reached the last available page of results. Please see the User Guide for more information.